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Abstract  42 
 43 
Background: Human milk (HM) transforming growth factor beta (TGF-β) is critical for inflammation 44 
regulation and oral tolerance promotion. Previous reports suggested that variations in HM TGF-β levels 45 
are associated with allergic outcomes. 46 
Objective: We undertook a systematic review (PROSPERO 2017 CRD42017069920) to reassess the 47 
evidence on the relationships between HM TGF-β and allergic outcomes in children. 48 
Methods: Electronic bibliographic databases (MEDLINE, EMBASE, Cochrane Library) were 49 
systematically searched. Two independent reviewers screened reference lists, extracted the data and 50 
assessed risk of bias using the National Institute for Clinical Excellence methodological checklist. 51 
Results: A total of 21 studies were identified. Sixteen studies assessed relationships between HM TGF-β 52 
and risk of eczema; 14, allergic sensitisation; 9, wheezing/asthma; 6, food allergy; 3, allergic 53 
rhinitis/conjunctivitis. Five cohorts (5/18, 28%) reported a protective effect of TGF-β1, while 3 (3/10, 54 
30%) suggested increased risk of allergic outcomes development and 1 (1/10, 10%), a protective effect of 55 
TGF-β2 on eczema. Meta-analysis was not possible due to significant heterogeneity in methodology, age 56 
of outcome assessment and differing statistical approaches. 71% (15/21) of studies carried a high risk of 57 
bias. 58 
Conclusion: In contrast with previous findings we did not find strong evidence of associations between 59 
HM TGF-β and allergic outcomes. Differences in studies’ methodology and outcomes do not allow 60 
unconditional rejection or acceptance of the hypothesis that HM TGF-β influences the risk of allergy 61 
development. Future studies on diverse populations employing standardised methods, accurate 62 
phenotyping of outcomes and evaluation of the effect of TGF-β in combination with other HM immune 63 
markers, microbiome and oligosaccharides are required. 64 
 65 
 66 
 67 
Key Messages 
• Basic science evidence suggests that human milk TGF-β is particularly important for oral 
tolerance development, with previous reports finding associations between TGF-β and 
immunological outcomes. 
• The evidence does not support previous conclusions with most of the studies finding null 
associations between human milk TGF-β and allergic outcomes in children. Studies lack 
methodological standardisation, resulting in high heterogeneity. 
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• Future research should focus on the assessment of multiple immune markers, human milk 
oligosaccharides and microbiome in relationship with the allergic outcomes, as it is highly likely that 
a combination, rather than a single factor contributes to potential protective effect. Standardisation 
of methodology, statistical analysis and outcome definitions should be considered a top priority for 
the future research to allow for data meta-analysis. 
 68 
 69 
 70 
 71 
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Abbreviations used  75 
AR: allergic rhinitis 76 
ARC: allergic rhinoconjunctivitis 77 
AS: atopic sensitization 78 
CI: confidence intervals 79 
CMA: cow’s milk allergy 80 
ELISA: enzyme-linked immunosorbent assay 81 
E: eczema 82 
FA: food allergy 83 
ISAAC: international study of asthma and allergies in childhood questionnaire 84 
MM: mature milk 85 
NICE: national institute for clinical excellence methodological checklists 86 
PRISMA: preferred reporting items for systematic reviews and meta-analyses guidelines 87 
HM: human milk 88 
HMO: human milk oligosaccharides 89 
OR: odds ratio 90 
slgE: specific immunoglobulin E 91 
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SPT: skin prick test 92 
TGF-β: transforming growth factor-beta 93 
TM: transitional milk 94 
RR: Relative risk 95 
 96 
Introduction 97 
Human milk (HM) is the main source of nutrition during early life, a critical period of metabolic and 98 
immune programming. It is well known that HM consists of essential macro- and micronutrients, vitamins, 99 
antibodies and many other bioactive factors, essential for the growth and development of a newborn infant 100 
1 and for protection against infections 2. However, there is conflicting evidence on the protective role of 101 
breastfeeding in relation to the development of allergic sensitization and allergic diseases 3 with children 102 
bearing the greatest burden of these increasingly prevalent conditions in modern relatively affluent 103 
environments 4. 104 
 105 
Transforming growth factor-beta (TGF-β) is a regulatory cytokine possessing pleiotropic functions, and 106 
is involved in physiological and pathological processes including embryogenesis, immune regulation and 107 
inflammation 5. Three TGF-β isoforms (TGF-β1, 2 and 3) are present in HM with TGF-β2 being a 108 
predominant type 6. TGF-β concentration varies considerably throughout lactation, with highest levels 109 
detected in colostrum 7, 8 followed by a rapid decline by 4-6 weeks of life 9-11 and a continuing decline by 110 
3 6, 12, 13 and 6 14 months postpartum. There has been an increasing interest in the role of HM TGF-β as a 111 
key immunoregulatory factor that promotes IgA production 6, 15, assists with mucosal repair in the neonatal 112 
gastrointestinal tract 16, acts as a co-factor helping in the generation of immune regulatory immune 113 
responses 17 and influences the neonatal gut microbiome 18. To date, the most comprehensive review of 114 
human studies was conducted a decade ago by Oddy and Rosales 19, reporting an association between 115 
KHALEVA & GRIDNEVA ET AL 
 
 
5 
TGF-β levels in HM and reduced risk of immunological outcomes in children in two-thirds of the studies. 116 
The authors suggested that presence of HM TGF-β may play an important role in gut immunity 117 
functioning and maturation, leading to the subsequent promotion of oral tolerance, thus reducing the risk 118 
of allergy development 19. High heterogeneity between the studies was highlighted, with maternal atopic 119 
status or dietary intervention during pregnancy and/or lactation suggested as the main reason. 120 
 121 
Despite suggested immunological benefits, the role of TGF-β in allergy prevention remains controversial. 122 
Discrepant findings may be partially related to the differences in milk collection methodology, sample 123 
storage and differences in laboratory approaches. In addition, studies employed different criteria for 124 
allergic predisposition of infants, definition of outcome, method of outcome assessment, environmental 125 
influence 20 and ethnicity 21. 126 
 127 
The importance of the links between HM composition and allergic disease development has received 128 
significant attention recently and objective assessment of existing evidence is timely. The aim of this 129 
systematic review is to summarise current knowledge on associations between HM TGF-β and 130 
atopy/allergy development. 131 
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Methods 132 
This systematic review is reported in accordance with the recommendations set forth by the Preferred 133 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 22. Methods were 134 
published apriori (PROSPERO 2017 CRD42017069920, available from: 135 
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017069920) on the 6th of July 136 
2017). 137 
Search strategy 138 
An extensive electronic search of MEDLINE, EMBASE and Cochrane Library was performed on the 7th 139 
June 2017, using both free text and MESH terms. The search strategies are provided as supplementary 140 
material (Table S1). At a screening stage, further studies were traced through cross-checking of reference 141 
lists from identified relevant papers. 142 
The relationships between TGF-β concentrations in HM (including colostrum, transitional milk, mature 143 
milk) and allergic diseases were studied. The primary outcome variables included atopic 144 
dermatitis/eczema, food allergy, asthma, allergic rhinitis, allergic conjunctivitis, allergic sensitization 145 
(skin prick test (SPT) and/or specific immunoglobulin E (sIgE) measurement) and serum immunoglobulin 146 
concentrations in infants and children. 147 
Eligibility criteria and selection of articles 148 
Studies of all designs were included if the following criteria were met: 1) Reported original data; 2) 149 
Clinical study of mother–infant dyads; 3) The study had an epidemiological design: observational studies, 150 
i.e. pregnancy cohort study, birth cohort study, human prospective study or randomized controlled trial, 151 
during pregnancy or lactation and interventional studies; 4) Included a quantitative assessment of TGF-β 152 
in HM; and 5) Investigated associations between HM TGF-β and at least one allergic disease or allergic 153 
KHALEVA & GRIDNEVA ET AL 
 
 
7 
sensitization in the child. We excluded reviews, conference abstracts, editorials, letters to the editor, case 154 
reports and/or case series. 155 
 156 
All included papers were transferred into EndNote reference manager. To reduce potential selection bias 157 
two independent investigators (EK and ZG) reviewed all titles and abstracts identified by the search for 158 
inclusion. Then EK and ZG independently reviewed full texts of all publications selected for data 159 
extraction. Any disagreements were resolved through discussion involving an additional reviewer (DM) 160 
and other co-authors if needed, until consensus was reached. 161 
 162 
Data extraction 163 
The data from each study were extracted in duplicate, tabulated, and included author and year of 164 
publication, descriptive information concerning the study design, country and setting, baseline 165 
characteristics of the study population, methodology of milk sampling, timing of sample collection, 166 
method of assessment of TGF-β concentration, outcome definition, age of outcome assessment, details on 167 
statistical analysis and overall TGF-β association with health outcome. 168 
 169 
Quality assessment 170 
The risk of bias was assessed in duplicate (EK and ZG) using the National Institute for Clinical Excellence 171 
(NICE) methodological checklist for cohort studies 23 and a final score was obtained by consensus. 172 
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Results  173 
Synthesis 174 
Based on the search strategy, a total of 353 titles were identified and 215 relevant abstracts were screened 175 
for eligibility (FIG.1). Of these, 26 met the inclusion criteria and were eligible for full-text assessment 176 
with 21 papers (reporting results from 20 study populations) included in our systematic review. One cohort 177 
study generated 2 publications 24, 25 and the results were summarised according to the study population, 178 
rather than by publication. Five studies were excluded as they did not assess any of the identified 179 
outcomes: 1 examined the effect of probiotic administration on the risk of eczema development and 180 
allergic sensitization only, without reporting the results on association with HM TGF-β 26, 2 studies 181 
investigated TGF-β in isolation from any allergic outcomes 27, 28, 2 studies assessed association between 182 
TGF-β and immunological but not allergic outcomes in infants 14, 15. Due to a limited number of studies 183 
reporting immunological outcomes, the scope of this systematic review is limited to allergic outcomes. 184 
However, as our initial search included search terms relevant for immunological outcomes, these are 185 
presented in a separate subsection. 186 
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 187 
FIG.1 PRISMA diagram of the systematic search and included studies. 188 
Description of the studies 189 
Twenty-one studies included in this systematic review have been published between 1999 and 2017 and 190 
can be grouped into 2 main categories in accordance with the design: (a) interventional 10-13, 29-31 and (b) 191 
observational 6, 21, 24, 25, 32-41 (Table I). All included interventional studies administered either single 10, 11, 192 
31 or multiple 12, 13, 29, 30 strains of probiotics for various durations during pregnancy 10-13 and/or lactation 193 
29-31 with exception of 1 study, which administered either formula or pasteurized HM 39. However, the 194 
analyses of interventional studies were undertaken within the studies without assessing the association 195 
between intervention and allergic outcomes in children. Ten studies measured TGF-β1 11, 24, 25, 30, 33, 34, 36-196 
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39, 41, 2 investigated TGF-β2 12, 29, 6 looked at both TGF-β1 and TGF-β2 6, 10, 21, 31, 32, 40 and 2 studies 197 
assessed all 3 TGF-β isoforms 13, 35. 198 
Participants characteristics 199 
Study populations included participants from 15 countries, with most research conducted in Scandinavia: 200 
7 studies in Finland 6, 12, 29, 31, 37, 39, 40 and 3 in Sweden 10, 21, 32; 3 in USA 24, 25, 34, 36; 2 in Italy 35, 38; and 1 in 201 
Australia 11, Denmark 33, Estonia 21, France 37, Germany 37, New Zealand  30, Norway 13, Russia 35, 202 
Switzerland 37, The Netherlands 41 and UK 35. 203 
Sample size ranged from 22 38 to 610 participants 37 while the maximum number of HM samples reached 204 
685 12. Most of the studies followed children up to the age of 24 months, the maximum age of follow-up 205 
was 72 months 37. Thirty-five percent of cohorts (7/20) recruited participants at high risk of allergy 206 
development (Table I). 207 
Stage of lactation  208 
Colostrum was collected within 0–4 days 6, 10, 12, 21, 29, 30, 32, 35, 38-40, transitional milk (TM) 5-14 days 11, 13, 209 
36 and mature milk (MM) between 15 days and 6 months postpartum 6, 10-13, 21, 24, 25, 30-34, 38, 41. Eight cohorts 210 
6, 10, 12, 21, 30, 32, 35, 38 measured TGF-β levels in paired colostrum and MM samples. Of the remaining cohorts, 211 
3 assessed TGF-β levels in colostrum 29, 39, 40; 1 in TM 36; 2 in TM and MM 11, 13 and 7 in MM 24, 25, 31, 33, 212 
34, 36, 37, 41. 213 
 214 
Methodology of human milk samples collection and storage 215 
The time of sample collection (time of the day, pre- or post-breastfeed) differed between the studies. 216 
Approaches to the sample collection varied with following sampling procedures reported: at the beginning 217 
of breastfeed 12, 41, during breastfeed (from the contra-lateral breast) 35, 41, at the end of breastfeed 11; 2 218 
hours after the previous breastfeed as a full breast expression or first 2 ounces 34; pooled samples from 2 219 
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breastfeeds if milk volume was low 12. Collection of the samples throughout the day also varied, with 4 220 
studies reporting morning collections 24, 36, 38, 41 and 16 not specifying the time. In 3 cohorts  HM was 221 
collected using electric breast pump 19, 24, 25, 41 while others used manual expression 10, 11, 21, 32, 35, 38 or 222 
collected the drip from contra-lateral breast during a breastfeeding session 35, 41. 223 
 224 
Upon collection the samples were either immediately frozen 21, 32 or maintained at room temperature from 225 
30 min up to 1 24, 25, 30, 4 36, 38 and 12 hours 35, 40 until transported to the laboratory, with most of the studies 226 
not fully specifying the storage/transit conditions. Identified differences in HM samples preparation 227 
methodology included: centrifugation of the samples before 10, 19, 24, 25, 32-35, 38, 41 or after freezing 6, 11-13, 21, 228 
29-31, 39, 40 and differences in acid treatment of the samples. 229 
 230 
Measurement of TGF- β in human milk 231 
Sixteen of 21 studies used enzyme-linked immunosorbent assay (ELISA) to quantify TGF-β levels in HM. 232 
Other techniques included: immunoassay 12, multiplex assay 13, custom-made multiplex assays 33, electro-233 
chemiluminescence 35 and quantikine immunoassay 40. There was a considerable heterogeneity in reported 234 
TGF-β concentrations, which made quantitative synthesis (meta-analysis) not possible. Lower levels of 235 
detection for TGF-β1 differed among the studies varying from 7 pg/ml 41 to 30 pg/ml 30, 36, 38 and 60 pg/ml 236 
21, 39 using ELISA, while detection levels for TGF-β2 were 60 pg/ml using both ELISA 21, 39 and 237 
immunoassay 12. 238 
 239 
Statistical analyses 240 
Studies included into this systematic review can be classified based on statistical methods used to address 241 
the research aim. Statistical approaches included: (a) univariate methods such as tests for groups 242 
comparison and univariate analysis of the variance (ANOVA); (b) classical multivariate regression to 243 
assess the association between risk factors and health outcome(s) adjusting for a number of confounders; 244 
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and (c) more advanced techniques such as least absolute shrinkage and selection operator (LASSO), 245 
principal components analysis (PCA) and causal mediation. Most of the studies performed univariate 246 
analysis with 15 studies carrying out only ANOVA and/or tests for group comparison such as t-test, chi-247 
square test, Fisher’s exact test and Mann-Whitney U-test. ANOVA was performed in 6 studies to assess 248 
time effect, treatment effect and/or the interaction effect on risk factors among groups. Ten studies 249 
performed multivariate logistic regression to estimate the association between risk factors and health 250 
outcome after adjusting for potential confounding factors, whilst 3 studies used more advance methods 251 
with 2 of them reporting detailed information on sensitivity analysis (Table SII). Eighteen studies did not 252 
report sample size power calculation, and none provided information on proportion of missing values 253 
among variables and methods used to handle missing values. 254 
 255 
Some studies reported ‘trends’, not supported by the statistical analysis results (P - values > 0.05) 10, 21, 29 256 
and only 3 studies 24, 25, 34 accounted for multiple comparisons. Half of the studies 10, 11, 13, 24, 25, 33-37 adjusted 257 
for potential confounders, including age, delivery mode, atopic status, length of breastfeeding, use of 258 
probiotics, site of collection, HM collection time, total storage time until analysis, introduction of food 259 
during the first year of life, paternal history of allergic diseases and presence of older siblings (Table SII). 260 
  261 
Allergic health outcomes measured 262 
Health outcomes were defined by clinical diagnosis 6, 10-13, 21, 29-32, 34, 38, 39, parental report 24, 35, 36, 41 and 263 
questionnaires with further clinical evaluation by the medical doctor 33, 37, 40 or based on well-validated 264 
instruments, such as “The International Study of Asthma and Allergies in Childhood” (ISAAC) study 265 
questionnaire 25, Hanifin and Rajka criteria 10, 29, 33 and UK Working party criteria 11-13, 30 for eczema. A 266 
single study obtained information on eczema diagnosis using both questionnaires with further evaluation 267 
by medical doctor, while wheezing was reported by parents 41. 268 
 269 
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Among health outcomes measured in this review, 16 (80%) population studies assessed the association 270 
between TGF-β concentration and risk of eczema, 9 (45%) asthma and/or wheezing, 6 (30%) food allergy 271 
development, 3 (15%) allergic rhinoconjunctivitis and 14 (70%) allergic sensitisation (Tables I, SIII). 272 
 273 
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  Reference 
(year of publication) 
N of 
participants/ 
milk samples ● 
Country Population ^ TGF-β assessed 
and method used 
Timing of sample 
collection 
Age at  
outcome 
(months) 
Health outcomes reported-β  
(method of assessment) 
Overall 
effect* 
 
 
Interventional studies 
Rautava 2002 31 62/NR Finland High risk  TGF-β1,2 
(ELISA) 
MM (3mo) 
 
24 E, CMA (clinical history, DBPC, SPT), AS (SPT)  
NS 
Bottcher 2008 10 109/109 Sweden High risk TGF-β1,2 
(ELISA) 
C (3d) 
MM (1mo) 
 
24 E (Hanifin and Rajka criteria), AS (SPT and/or sIgE) –  
(AS) 
Huurre 2008 29 140/NR Finland High risk TGF-β2 
(ELISA) 
C (0d) 12 AS (SPT)  
NS 
Prescott 2008 30 105/105 New Zealand High risk TGF-β1 
(ELISA) 
C (3-7d) 
MM (1, 3mo) 
 
24 E (UK Working party criteria), AS (SPT)  
NS 
Kuitunen 2012 12 NR/278 ● Finland      High risk           TGF-β2 
(Immunoassay) 
C (0-3d) 
MM (3mo) 
 
60 ■ 
 
FA (OFC); E (UK Working party criteria); 
A, AR (DD) ♦ 
– 
(E, AD) 
Ismail 2013 11 79/79 Australia High risk TGF-β1 
(ELISA) 
TM (7d) 
MM (28d) 
 
12 E (UK Working party criteria), AS (SPT), IgE-
associated E (positive SPT) 
 
NS 
Simpson 201613 259/259  Norway Normal risk TGF-β1-3 
(Multiplex assay) 
TM (10d) 
MM (3mo) 
  
24 E (UK Working party criteria), AS (SPT and/or slgE)  
NS 
Observational studies 
Kalliomaki 19996 47/43 ● Finland Normal risk TGF-β1,2 
(ELISA) 
C (0d) 
MM (3mo) 
 
12 E (Hanifin and Rajka criteria) + 
(E) 
Saarinen 1999 39 325/NR Finland Normal risk TGF-β1 
(ELISA) 
C (1-4d) 
 
3-13 CMA (Typical symptoms, SPT, sIgE), AS (positive 
SPT or sIgE) 
+ 
(AS) 
Bottcher 200332 53/53 Sweden Normal risk TGF-β1,2 
(ELISA) 
C (0-4d) 
MM (1mo) 
 
24 AS (SPT); A,E,ARC (DD) ♦  
NS 
Oddy 2003 36 243/142 ● USA Normal risk TGF-β1 
(ELISA) 
TM (14d) 
 
12 W (Parental-reported) + 
(W) 
Savilahti 2005 40 228/227 ● Finland Normal risk TGF-β1,2 
(Quantikine 
Immunoassay) 
 
C (1-4d) 
48 CMA, E, A, AR, AC (questionnaire, paediatrician 
evaluation), AS (SPT, slgE) 
 
NS 
Rigotti 2006 38 22/22 Italy Normal risk TGF-β1 
(ELISA) 
C (3d) 
MM (1mo) 
 
6 
 
E (paediatrician evaluation)  
NS 
Snijders 2006 41 315/307 ● The 
Netherlands 
Normal risk TGF-β1 
(ELISA) 
MM (1mo) 
 
24 ■■ E (ISAAC questionnaire, UK Working party 
criteria), W (Parental-reported), AS (sIgE) 
 
NS 
Tomicic 2010 21 99/99 Estonia, 
Sweden 
Normal risk TGF-β1,2 
(ELISA) 
C (0-4d) 
MM (1mo) 
 
24 AS (SPT and/or slgE); 
E (DD) 
 
NS 
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Table I. Characteristics of the included studies A, asthma; AD, allergic diseases (cumulative outcome); AR, allergic rhinitis; ARC, allergic rhinoconjunctivitis; AS, allergic sensitization; C, colostrum 
(0-4 days) CMA, cow’s milk allergy; D, days; DBPCFC, double-blind placebo-controlled food challenge; DD, doctor diagnosis; E, eczema; ELISA, enzyme-linked immunosorbent assay; FA, food 
allergy; ISAAC, International Study of Asthma and Allergies in Childhood; MM, mature milk (2 weeks and later); MO, months; NR, not reported; OFC, oral food challenge; SPT, skin prick test; sIgE, 
specific IgE levels; TGF-β, transforming growth factor-beta; TM, transitional milk (5-14 days); W, wheezing. 
■ SPT with common allergens and/or slgE were assessed and associations between TGF-β and eczema reported up to 2 years; ■■ Eczema was evaluated up to 12 months; ■■■ Eczema was evaluated up to 
4 years.  * overall effect of TGF-β1-3: “NS” - no significant effect; “+” - protective effect, “–” - higher risk of development of any reported allergic disease and/or allergic sensitization. ^ Children at high 
risk of allergy development were identified based on allergic history of mothers and/or family history. ● Number of analysed milk samples for TGF-β concentration unless not reported. ♦ Some allergic 
outcomes were combined for the purpose of statistical analyses. 
Soto-Ramirez 
2012 25 
2016 24 
178/115  USA Normal risk TGF-β1 
(ELISA) 
MM (21d) 
 
12 Scratching (questionnaires); asthma-like symptoms 
(ISAAC questionnaire) 
+ 
(W) 
 
Joseph 201434 304/304 USA     Normal risk TGF-β1 
(ELISA) 
MM (1mo) 
 
36 FA (DD), AS (SPT, slgE) + 
(AS) 
Orivuori 2014 37 610/610 Finland, 
France, 
Germany, 
Switzerland 
    Normal risk TGF-β1 
(ELISA) 
MM (2mo) 
 
72 ■■■ E and A (questionnaires, DD), AS (slgE)  
NS 
Jepsen 2016 33 223/223 Denmark High risk  TGF-β1 
(custom-made 
Multiplex Assay) 
MM (1mo) 
 
36 E (Hanifin and Rajka criteria), W (daily diaries, DD)  
NS 
Munblit 201735 398/315 UK, Italy, 
Russia 
Normal risk TGF-β1-3 
(Electro-
chemiluminescence) 
C (0-6d) 
MM (1mo) 
 
6 E, FA, W (Parental- reported), AS (SPT)         – 
(E) 
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TGF-β and development of allergic diseases 274 
Overall, 60% of study populations in the review (12/20) showed no associations with HM TGF-β, 5/20 275 
(25%) – protective effect and 3/20 (15%) – higher risk of allergy development (Tables I and SIII; FIG.2). 276 
TGF-β1 showed either no or some protective effect (5/18, 28%) on infant allergic outcomes, while 277 
conflicting results coming from TGF-β2 studies, with 3 studies (3/10, 30%) reporting high risk of allergy 278 
development and 1 (1/10, 10%) – protective effect of TGF-β2 (FIG.3). TGF-β3 showed no associations 279 
with allergy development or allergic sensitisation 13, 35. Five out of 15 individual health outcomes assessed 280 
at children below 2 years of age were associated with TGF-β in HM. Out of 30 individual health outcomes 281 
assessed at 2 years of age and beyond, only 3 were associated with the levels of TGF-β in HM (FIG.2). 282 
 283 
 284 
FIG.2. Matrix of associations between TGF-β (cumulatively isoforms 1,2 and 3) in human milk and allergic 285 
outcomes at different age of outcome assessment. Horizontal lines indicate age of outcome assessment and vertical 286 
lines indicate allergic outcomes. Blue circle size indicates the total number of studies representing the matrix point 287 
and internal, smaller circles, indicate the number of studies showing positive (green circle)/negative (red circle) 288 
association between TGF-β and given allergic outcome, if available. Y.O. – years old, MO. – months. 289 
High risk Protective effect 
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FIG.3. Summary of associations between different isoforms of transforming growth factor beta in human milk and allergic 293 
outcomes in children. Colored boxes show significant positive (green) or negative (red) association between TGF-β and 294 
particular allergic outcome. * Allergic outcomes in this study were combined for the purpose of statistical analyses. 295 
 296 
TGF-β and eczema 297 
No consistent association was found between HM TGF-β and development of eczema. Among 15 studies 298 
6, 10-13, 21, 24, 30, 31, 33, 35, 37, 38, 40, 41, only 2 reported higher risk of eczema development in children exposed to 299 
HM with higher TGF-β2 levels. According to Munblit et al., infants receiving higher levels of mature 300 
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milk TGF-β2 were at higher risk (OR, 1.04; 95% CI, 1.01-1.06) of eczema development at 6 months 35. 301 
Notably, Kuitunen et al. reported no association between TGF-β2 in colostrum and eczema, but higher 302 
TGF-β2 concentration in mature milk was associated with eczema at 2 years of life 12. For TGF-β1, 303 
Kalliomaki et al. found higher concentrations in colostrum of mothers of infants with post-weaning onset 304 
of eczema compared with those with no and pre-weaning onset of disease 6. 305 
 306 
TGF-β and food allergy 307 
No association between TGF-β in HM and development of food allergy was reported 31, 34, 35, 39, 40, with 308 
an exception of Saarinen et al. study, as authors reported concentration of TGF-β1 in colostrum of mothers 309 
of infants with non IgE-mediated cow’s milk allergy was significantly higher (mean 1162; 95% CI 881-310 
1531) pg/ml) than in IgE-mediated cow’s milk allergy (589; 413-840) and healthy individuals (807; 677-311 
963 pg/ml) 39. 312 
TGF-β and allergic sensitization 313 
Among 20 cohorts 10, 11, 13, 21, 29-32, 34, 35, 37, 39-41 14 investigated relationship between HM TGF-β and allergic 314 
sensitization with only two reporting protective effect and one associated with high risk. Bottcher et al. 315 
found lower levels of TGF-β2 (<701 pg/ml) in colostrum of mothers of non-sensitized children at 24 316 
months of age (OR, 0.3; 95% CI, 0.1-0.9), although higher levels (>1400 pg/ml) were not associated with 317 
an increased risk of sensitization at 6 months of age (OR, 5.0; 95% CI, 0.9-27; P = .06) 10. Saarinen et al. 318 
39 reported weak negative correlation between the concentration of colostrum TGF-β1 and SPT diameter 319 
to cow’s milk (r = -0.23; P = 0.02), β-lactoglobulin (r = -0.35, P = .01) and stimulation index to α-casein 320 
(r = -0.28, P = .04) measured in infants with cow’s milk allergy at the time of the challenge. In the study 321 
of Joseph et al., among non-atopic mothers HM TGF-β1 concentrations were lower for those infants 322 
classified as allergen-specific sIgE (1347, 1134-1600 vs. 1651, 1427-1910 pg/ml respectively, P = .047) 323 
but among atopic mothers concentrations for these infants were higher (2161, 1868-2499 vs. 1525, 1347-324 
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1726 pg/ml, P = .001), with no significant difference in concentration when stratified by positive SPT 34. 325 
Orivuori et al. reported no consistent results at 4 and 6 years, however, at 6 years adjusted logistic 326 
regression models for IgE cut-off of 3.5 kU/l, but not for 0.35 and 0.7 kU/l, showed a significant difference 327 
(aOR, 95% CI : Q1, 0.40, 0.18-0.90, P < 0.05; Q2, 0.26, 0.11-0.61, P < 0.01) 37. 328 
 329 
TGF-β and asthma/recurrent wheezing 330 
Seven studies investigated associations between HM TGF-β and either asthma 37, 40 or recurrent wheezing 331 
25, 33, 35, 36, 41. Most of the studies reported no significant findings with only 2 detecting a protective effect 332 
of TGF-β1. In adjusted analyses, Soto-Ramirez et al. found that infants exposed to higher levels of TGF-333 
β1 in mature HM had a lower risk of  development of asthma-like symptoms at 6 and 12 months (RR = 334 
0.31 (0.13-0.76) and 0.26 (P = 0.01) respectively) 25. Similarly, Oddy et al. found a smaller percentage of 335 
wheeze in infants that received a higher dose of TGF-β1 through transitional HM (P = 0.02) 36. 336 
 337 
TGF-β and allergic rhinitis/allergic rhinoconjunctivitis 338 
The association between HM TGF-β levels and allergic rhinitis and/or allergic rhinoconjunctivitis was 339 
assessed in one cohort only, with no significant associations found 40. 340 
 341 
TGF-β and immunological outcomes 342 
Although our systematic review is focused on allergic outcomes, the initial search included search terms 343 
for immunological outcomes, so we provide an overview of the existing studies approaching this topic. 344 
Ogawa et. al. studied associations between TGF-β1 and TGF-β2 in colostrum of healthy mothers and 345 
serum IgA in newborns during the first month of life 15. Notably, an increase of serum IgA in infants from 346 
birth to 1 month of life correlated with levels of both TGF-β1 (r = 0.38, P = .005) and TGF-β2 (r = 0.45, 347 
P < 0.001), while increase of IgM marginally correlated only with TGF-β2 (r = 0.28, P = 0.04) suggesting 348 
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that colostral TGF-β may serve as the stimulus for IgA production in newborn infants. In line with this 349 
notion, Saarinen et al. found a positive correlation between TGF-β1 in colostrum and both, IgA antibodies 350 
to β–lactoglobulin (r = 0.204, P = 0.04) and IgG antibodies to α-casein (r = 0.237, P = 0.02) in infants 351 
prone to CMA 39. Moreover, the size of SPT to CM (r = -0.228, P = 0.02) was negatively associated with 352 
the level of TGF-β1, indicating that TGF-β1 may inhibit IgE-mediated reactions to CM. Comparatively, 353 
TGF-β2 concentration in colostrum has been reported to associate with specific IgA responses to dietary 354 
antigens at 3 months of age (P = 0.048) 6. In contrast, Prokesova et. al. investigated changes in the immune 355 
system of children genetically predisposed to allergic diseases reporting no significant differences in 356 
concentrations of TGF-β in colostrum and mature HM of allergic mothers compared with non-allergic 357 
mothers 14. Although differences in concentrations of serum cytokines (IL-4, IL-10, IFN-γ) between the 358 
groups of healthy and high risk infants were reported, no analysis was conducted to test for associations 359 
between concentrations of HM TGF-β and these immunological outcomes 14. The latter study, while 360 
reporting TGF-β concentrations in mature HM beyond the first month of lactation, did not diﬀerentiate 361 
between TGF-β isoforms. Difference in methodology, study design and immunological outcomes 362 
assessed does not allow for an appropriate analysis of these data. 363 
Risk of bias 364 
All the studies included in this systematic review were evaluated for their quality, with most being of a 365 
medium quality (FIG.3). High risk of bias was detected in 15 studies (71%). The main issues identified 366 
were attrition, selection and detection bias, including lack of adjustment for potential confounders and the 367 
use of self-reported questionnaires as a tool for allergic outcomes assessment. 368 
It is worth noting that asthma diagnosis at the age below 3 years was considered an unreliable outcome as 369 
most children with “early wheeze” do not develop subsequent asthma 42. We also considered any allergic 370 
outcome based on non-validated questionnaires without following clinical examination by doctor as a 371 
high risk of bias. We acknowledged any adjustments for known confounders performed by the authors, 372 
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but there is no clear guidance which adjustments are imperative. Attrition bias was calculated for all 373 
participants as it is not always clear if the same participants provided samples and completed the follow 374 
up; high attrition bias was considered as ≤75%. 375 
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 376 
Fig.3 Risk of bias in studies assessing association between TGF-β concentration in human milk and allergic outcomes using 377 
the National Institute for Clinical Excellence methodological checklist. ‘+, green’, low risk of bias; ‘-, red’, high risk of bias; 378 
‘?, yellow’, unclear risk of bias. 379 
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Discussion 380 
In this systematic review, we summarised findings of 21 studies from 20 cohorts of associations between 381 
HM TGF-β and allergic outcomes in infancy and childhood. Data from included studies showed no strong 382 
association between any isoform of TGF-β in HM and atopy/allergy development. Twelve new studies 383 
were identified 10-13, 21, 24, 25, 29, 33-35, 37 since the last systematic review19, but evidence remains limited, due 384 
to high heterogeneity between studies, which makes any quantitative synthesis impossible. We used robust 385 
methods to search and synthesize evidence, provided critical analysis, identified several key strengths and 386 
limitations in the current literature and highlighted the unmet needs. In this paper, we provide a 387 
comprehensive overview of relationships between the levels of TGF-β in HM and allergic outcomes. 388 
Although it was not possible to perform a meta-analysis, qualitative synthesis suggests that there is 389 
insufficient evidence of TGF-β influence on atopy/allergy development. Out of 15 studies only 3 found 390 
significant associations between TGF-β and eczema, 3 out of 14 with allergic sensitisation, 2 out of 9 with 391 
wheezing/asthma and none out of 5 linked TGF-β with IgE-mediated food allergy development. These 392 
results, however, do not completely exclude the possibility of TGF-β to impact allergic diseases 393 
development as a protective or negative effect was reported in some studies, with TGF-β1 being 394 
predominantly related to a protective effect and TGF-β2 associating with a higher risk of allergic disease. 395 
Studies differed in methods applied and outcomes reported and in addition to methodological 396 
heterogeneity, most of the studies carried a high risk of bias, thus results should be interpreted with 397 
caution. 398 
Across a limited number of studies suggesting associations between the levels of HM TGF-β and allergic 399 
outcomes, opposite effects are generally reported for TGF-β1 and TGF-β2 isoforms. TGF-β1 is mainly 400 
associated with the protective effect, while TGF-β2 is linked with a higher risk of atopy/allergy 401 
development. There is increasingly more evidence, suggesting that TGF-β acts as a bi-functional 402 
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regulator, with its context-dependent nature of activities confirmed in a variety of biological responses 403 
and cell systems 43. All TGF-β isoforms share a characteristic structure and are highly pleiotropic, but 404 
each isoform is linked with specific functions, therefore, may exert different effects. While TGF-β2 405 
presents in much higher concentrations, accounting for up to 95% of TGF-β in HM, it is less potent than 406 
TGF-β1 44-46. TGF-β1-deficient mice were linked with the neonatal inflammatory disease 47, whereas 407 
TGF-β2,3-deficient mice present with developmental defects 48, 49. This indicates that HM TGF-β 408 
isoforms may indeed have differential effects on allergy development. 409 
 410 
HM contains a plethora of immune moderators 50, which may have synergistic and/or antagonistic effects 411 
to TGF-β, thus subsequently influencing the risk of atopy/allergy development. A recent study has 412 
investigated the effect of the immunological milieu of HM including 28 cytokines, chemokines and 413 
growth factors on development of cow’s milk allergy. The authors reported interactions between the 414 
immune markers and showed that networks of HM regulatory and pro-inflammatory cytokines including 415 
TGF-β1, IL-1β, IL-6 and IL-10 are associated with tolerance to cow’s milk development 51. These findings 416 
suggest that narrowing research to single components could result in conflicting and even misleading 417 
findings and suggests that HM studies should implement a more holistic approach given the links between 418 
development of the immune system and both the gut microbiome 52 and HM oligosaccharides (HMO) 53. 419 
 420 
We found a high degree of heterogeneity between studies, with differences in methodology (sample 421 
collection, storage and processing), populations (general population and high risk), outcome definition, 422 
age at outcome assessment, and approaches to statistical analysis being the most important contributors. 423 
Lack of standardized protocols of HM sample collection, storage and processing is an important issue, 424 
influencing the quality of HM research 54, associated with heterogeneity and not allowing for quantitative 425 
synthesis. 426 
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 427 
Previous research linked a number of physiological and environmental factors with the changes of TGF- 428 
β levels in HM. Stage of lactation and time of sample collection 9, circadian and seasonal variations 55, 56, 429 
time prior to freezing and length of sample storage 57, differences in laboratory techniques 55, ethnicity 34, 430 
residency 21, maternal lifestyle 35, smoking 37, diet 58, infection 59 as well as depression and anxiety 56, 60 431 
were found to be a confounders and appear to impact TGF-β concentrations, thus possibly impacting 432 
health outcome development. Very few studies collected sufficient information and accounted for the 433 
duration and exclusivity of breastfeeding. Absence of this information prevents in-depth analysis of the 434 
dose-dependent effect. Although examination of associations between colostrum concentrations of HM 435 
components and infant outcomes is usually straightforward, the investigation of relationships with 436 
concentrations in mature HM is more problematic, given the variability in breastfeeding patterns and 437 
volumes of HM consumed during the lactation 61. Our systematic review highlights pitfalls in HM 438 
research, with results not being data adjusted for known confounding factors in many studies up to date 439 
with only a few using multivariate statistical analysis (Table SII). 440 
 441 
Differences in statistical methods applied largely contributed to the results of this review, with a large 442 
variety of strategies employed, yet lacking comprehensive approach and consistency. The issues 443 
associated with carrying out multiple hypothesis tests were rarely considered leading to a high risk of 444 
false-positive results and missing data was common but not dealt with, possibly resulting in under- and/or 445 
over-estimation of association between the exposure and outcome 62. Adjustment for potentially important 446 
confounding factors may play an important part in identifying associations between levels of TGF-β and 447 
infant allergic outcomes but 6 studies did not report any adjustment. With heterogeneity in sample 448 
collection and processing, another important factor making meta-analysis impossible was data reporting, 449 
with some presenting adjusted and others non-adjusted data. In some studies data was not reported, 450 
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particularly if associations were not found to be significant. The different designs of the studies, e.g. 451 
observational and interventional, make it difficult to compare the results, as potential influence of the 452 
intervention cannot be excluded. 453 
 454 
Health outcome definitions significantly varied between the studies contributing to heterogeneity. Some 455 
studies used  less reliable measurements such as infant itchy rash 35, scratching 24 or asthma-like symptoms 456 
25. Parental-reported allergic outcomes are not always accurate and the possibility of overdiagnosis cannot 457 
be ruled out. It has been previously shown that mothers tend to over-report eczema in their children 63. It 458 
should be noted, however, that most of the studies verified parental reports by physician assessment or 459 
used well-validated tools, such as the ISAAC questionnaire 64 or eczema UK Working party criteria 65. 460 
There is also a marked difference in the age of health outcome assessment across the studies, ranging 461 
between 6 months and 6 years of age. Thirty percent of individual health outcomes assessed in children 462 
below 2 years of age were associated with TGF-β in HM, while only 3 out of 30 health outcomes at 2 463 
years of age and beyond were found to be linked with TGF-β levels. This makes impact of HM TGF-β on 464 
allergic outcomes improbable and even if it exists in selected populations, it is highly unlikely that it 465 
extends beyond 2 years of age.   466 
 467 
Atopic march theory suggests that allergic diseases progress from inflammatory skin manifestations, such 468 
as eczema during infancy, to asthma and allergic rhinitis in later childhood 66. It has been demonstrated 469 
that many “early wheezers” do not subsequently develop persistent asthma 42. There may even be an 470 
inverse relationship between early infection-induced wheeze and subsequent asthma 67. It should be noted 471 
that most of the studies assessing asthma included in this systematic review, were realistically measuring 472 
wheeze rather than asthma, as age at health outcome assessment does not allow for appropriate asthma 473 
diagnosis. Apart from the Orivuori et al. diagnosing asthma at 6 years of life 37, no other study measured 474 
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this health outcome beyond the age of 4 years. Considering lack of studies reporting doctor’s diagnosed 475 
health outcomes there is a need in further prospective cohorts, using well-validated instruments and 476 
standardized definitions, assessments of allergic outcomes and a considerable follow-up to evaluate the 477 
persistency of allergic symptoms. 478 
 479 
The most recent systematic review 19 provided an overall measure of the effect of HM TGF-β on 480 
immunological outcomes in infants and children and reported that 8 out of 12 studies showed a positive 481 
association between either TGF-β1 or TGF-β2 concentrations and a reduction in allergy-related outcomes. 482 
These results are in conflict with our findings, which may be explained by the difference in systematic 483 
review inclusion criteria. Oddy and Rosales reviewed all the studies reporting any immunological, 484 
biochemical and/or clinical outcomes, including those assessing associations between maternal allergic 485 
status and HM TGF-β concentration, while this paper reviews associations between HM TGF-β and 486 
atopy/allergy development in offspring only. 487 
Conclusion 488 
TGF-β is an important immunological factor involved in inflammation regulation. Biological effects of 489 
HM TGF-β on allergic outcomes during infancy and childhood need to be further elucidated. Although 490 
several associations have been observed between HM TGF-β and allergic outcomes, our updated 491 
systematic review did not find strong evidence of association between the levels of TGF-β in HM and 492 
atopy/allergy development. Studies would benefit from an investigation into any dose-dependent effect, 493 
with an apparent lack of studies measuring exact amounts of breast milk consumed, in addition to 494 
immuno-active molecules measurement. Future studies should employ standardised, validated methods, 495 
accurate phenotyping of outcomes, use of comprehensive and consistent statistical methods to enable 496 
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meta-analyses. Implementation of a more holistic approach, assessing multiple immune markers level, 497 
HMO and microbiome would improve the quality of the research in the field. 498 
 499 
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TABLE S1. Search strategies. 698 
Embase Classic+Embase <1947 to 2017 June 7> (via Ovid) 699 
1     allergy/ or hypersensitivity/ or immunoglobulin/ or immunoglobulin a/ or immunoglobulin a1/ or 700 
immunoglobulin a2/ or immunoglobulin e/ or secretory immunoglobulin/ 701 
2     (allergy or allergic diseases or allerg* or immun* outcomes or eczema or atopic dermatitis or itchy 702 
rash or allergic rhinitis or hay fever or food allergy or food hypersensitivity or asthma or wheeze or 703 
respiratory hypersensitivity or eosinophilic esophagitis or Ig serum level or immunoglobin blood level or 704 
immunoglobulin level or immunoglobulin serum level or plasma immunoglobulin or serum 705 
gammaglobulin or serum immune globulin or IgA or IgA1 or IgA2 or immunoglobulin A or IgE or 706 
immunoglobulin E or secretory immunoglobulin).mp. [mp=title, abstract, heading word, drug trade name, 707 
original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading 708 
word] 709 
3     food allergy/ or hypersensitivity/ 710 
4     asthma/ or allergic asthma/ 711 
5     wheezing/ 712 
6     eczema/ or dermatitis/ 713 
7     1 or 2 or 3 or 4 or 5 or 6 714 
8     transforming growth factor/ or transforming growth factor beta/ 715 
9     (Transforming growth factor beta or transforming growth factor beta1 or transforming growth factor 716 
beta2 or transforming growth factor beta3 or TGF beta or TGFbeta or TGF-beta or TGF*).mp. [mp=title, 717 
abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device 718 
trade name, keyword, floating subheading word] 719 
10     8 or 9 720 
11     colostrum/ 721 
12     human milk.mp. or breast milk/ 722 
13     (breast milk or breast milks or human milk or milk or breast milk human or mature milk or colostrum 723 
or early milk or transitional milk).mp. [mp=title, abstract, heading word, drug trade name, original title, 724 
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word] 725 
14     11 or 12 or 13 726 
15     (child* or infant* or boy* or girl* or newborn*).mp. [mp=title, abstract, heading word, drug trade 727 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating 728 
subheading word] (3306386) 729 
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16     child/ 730 
17     infant/ 731 
18     newborn/ 732 
19     15 or 16 or 17 or 18 733 
20     7 and 10 and 14 and 19 734 
 735 
Cochrane library 736 
1. “allergy” or allergic diseases or allerg* or immun* outcomes or “eczema” or “atopic dermatitis” 737 
or itchy rash or “allergic rhinitis” or “hay fever” or “food allergy” or food hypersensitivity or “asthma” or 738 
“wheeze” or respiratory hypersensitivity or eosinophilic esophagitis or Ig serum level or immunoglobin 739 
blood level or “immunoglobulin” or immunoglobulin level or immunoglobulin serum level or plasma 740 
immunoglobulin or serum gammaglobulin or serum immune globulin or “IgA” or IgA1 or IgA2 or 741 
“immunoglobulin A” or “IgE” or “immunoglobulin E” 742 
2. “Transforming growth factor beta” or “transforming growth factor beta 1” or “transforming 743 
growth factor beta 1 level” or “transforming growth factor beta1” or “transforming growth factor beta 2” 744 
or “transforming growth factor beta 3” or TGF beta or TGFbeta or TGF-beta or TGF* 745 
3. “breast milk” or breast milks or human milk or milk or breast milk human or colostrum* or 746 
“colostrum” or mature milk or transitional milk 747 
4. child* or “child” or infant* or “infant” or boy* or girl* or newborn* or “newborn” 748 
5. #1 and #2 and #3 and #4 749 
 750 
Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid 751 
MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present> 752 
1     hypersensitivity/ or conjunctivitis, allergic/ or dermatitis, atopic/ or eosinophilic esophagitis/ or food 753 
hypersensitivity/ or respiratory hypersensitivity/ or asthma/ or rhinitis, allergic/ or urticaria/ or 754 
immunoglobulins/ or serum globulins/ or Immunoglobulin E/ or blood immunoglobulins.mp. or 755 
immunoglobulin a.mp. or Immunoglobulin A/ 756 
2     (allergy or allergic diseases or allerg* or immun* outcomes or eczema or atopic dermatitis or itchy 757 
rash or allergic rhinitis or hay fever or food allergy or food hypersensitivity or asthma or wheeze or 758 
respiratory hypersensitivity or eosinophilic esophagitis or Ig serum level or immunoglobin blood level or 759 
immunoglobulin level or immunoglobulin serum level or plasma immunoglobulin or serum 760 
gammaglobulin or serum immune globulin or IgA or IgA1 or IgA2 or immunoglobulin A or IgE or 761 
immunoglobulin E).mp. [mp=title, abstract, original title, name of substance word, subject heading word, 762 
keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, 763 
unique identifier, synonyms] 764 
3     1 or 2  765 
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4     transforming growth factor beta/ or transforming growth factor beta1/ or transforming growth factor 766 
beta2/ or transforming growth factor beta3/ 767 
5     (Transforming growth factor beta or transforming growth factor beta1 or transforming growth factor 768 
beta2 or transforming growth factor beta3 or TGF beta or TGFbeta or TGF-beta or TGF*).mp. [mp=title, 769 
abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 770 
supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] 771 
6     4 or 5  772 
7     Milk, Human/ or Colostrum.mp. [mp=title, abstract, original title, name of substance word, subject 773 
heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary 774 
concept word, unique identifier, synonyms] 775 
8     (breast milk or breast milks or human milk or milk or breast milk human or colostrum* or mature 776 
milk or transitional milk).mp. [mp=title, abstract, original title, name of substance word, subject heading 777 
word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept 778 
word, unique identifier, synonyms] 779 
9     7 or 8  780 
10     adolescent/ or child/ or child, preschool/ or infant/ or infant, newborn/ or infant, low birth weight/ 781 
or infant, postmature/ or infant, premature/ 782 
11     (child* or infant* or boy* or girl* or newborn*).mp. [mp=title, abstract, original title, name of 783 
substance word, subject heading word, keyword heading word, protocol supplementary concept word, 784 
rare disease supplementary concept word, unique identifier, synonyms] 785 
12     10 or 11 786 
13     3 and 6 and 9 and 12 787 
 788 
 789 
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TABLE SII. Statistical analyses of association TGF- β in HM and allergic outcomes 
Study Statistical analyses of association between groups and between TGF-β 
in HM and allergic outcomes 
Data expression 
and outcomes 
reported 
Data transformation and adjustment to 
potential confounders 
Interventional studies 
Rautava 
2002 31 
The Student t-test for comparison of values between groups for normally distributed 
data. 
Mann-Whitney U-test for comparisons between groups for data of skewed distribution. 
The Chi-squared test for comparisons of proportions between groups. 
Mean (95%CI) 
Median (IQR) 
NR 
Bottcher 
2008 10 
Mann-Whitney U-test for unpaired analyses. 
Spearman's rank order correlation coefficient test for correlations analyses. 
Multiple logistic regression and ANOVA for analyses of multivariate relationships.  
Mean (range) 
OR (95% CI) 
r 
Study treatment (placebo or L. reuteri) 
Maternal atopy 
Na/K ratios 
Huurre 
2008 29 
Mann-Whitney U-test, w2 test, the t-test for the baseline and clinical characteristics. 
The association between infant sensitization and TGF-β tertiles (T1, T2 and T3) was 
given descriptively. 
GM (95% CI) 
Probiotic/placebo 
ratios (95% CI) 
* Logarithmically transformed 
NR 
Prescott 
2008 30 
Mann-Whitney test for differences between the groups for non-parametric data.  
Chi-square or Fisher’s exact test for differences between the groups for dichotomous 
data. Spearman or Kendall’s Tau for correlations. 
Median (IQR) 
τ 
Factors with potential confounding effects were tested by 
correlation analyses. 
NR 
Kuitunen 
2012 12 
Mantel-Haenszel method for the association between HM variables and allergic 
outcomes by the ages of 2 and 5 years in the treatment groups separately. 
The Breslow-Day test for evaluation whether the association is different in the 
probiotic group from that of the placebo group. 
GM (95% CI) 
OR (95% CI) 
* Logarithmically transformed 
Assessed separately by treatment group if Breslow-Day 
test indicated interaction 
 
Ismail 
2013 11 
The Student’s t-test for normally distributed continuous data. 
Mann-Whitney U-test was for skewed data. 
Chi-squared test or Fisher’s exact test for categorical data. 
Logistic regression analyses. 
Mean (SEM) 
GM (95% CI) 
Median (IQR) 
* Skewed data log10-transformed 
Treatment group 
Maternal allergic status 
Simpson 
2016 13 
Wilcoxon matched-pairs signed-rank test for comparison of the concentration at 10 
days and 3 months. 
Linear regression for effect of probiotic supplementation on TGF-β concentrations.  
Causal mediation analysis (paramed) for HM cytokines which were found to be altered 
by probiotic supplementation. 
Median (IQR) 
RR 
 
Maternal atopy 
Maternal smoking during the first year of life 
Presence of older siblings 
 
Observational studies 
Kalliomaki 
1999 6 
The Fisher exact test or chi-squared test for differences in contingency tables.  
The Kruskal-Wallis test for comparisons between the groups. 
The Mann-Whitney U-test and Wilcoxon signed-rank test for comparisons between 2 
unpaired and paired groups, respectively. 
Spearman rank correlation for correlation between 2 variables. 
Median (IQR) 
% 
r 
NR 
Saarinen 
1999 39 
ANOVA was used for multiple comparisons. 
2-tailed Student’s t-test for comparisons between groups. 
Spearman rank correlation test for correlations between measurement from colostrum 
samples and from infants with CMA. 
Mean (95%CI) 
r 
* Logarithmically transformed 
Maternal atopy tested, NS 
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Bottcher 
2003 32 
Mann-Whitney U-test rank test for groups comparison. 
Spearman’s rank order correlation coefficient test for correlations. 
The chi-square test for categorical variables, and Fisher’s exact test for when the 
expected frequency for any cell was less than 5. 
Median, 
Frequency (%) in 
groups 
NR 
Oddy 
2003 36 
Spearman nonparametric tests for correlation coefficients between cytokines. 
Contingency tables and the chi-square test for relationship between breastfeeding and 
wheeze in the first year of life. The relationship of the concentration of each cytokine 
in milk to wheeze was assessed by dividing the concentrations into tertiles with trend 
chi-square tests. 
Logistic regression analyses to determine the odds for any wheeze associated with 
cytokine dose in milk. 
A final categorization of concentration and duration of breastfeeding was calculated 
to reflect short or long duration of feeding (divided at the median in weeks) and low 
vs. medium-high cytokine concentration. 
Mean (95%CI) 
OR (95%CI) 
r 
Maternal characteristics: smoking at 1 year (any vs. none), 
education (≤12 vs. >12 years), history of physician-
diagnosed asthma (yes vs. no) 
Offspring characteristics: sex, gestational age (<37 vs. 
≥37 weeks), birth weight (≤6 lbs vs. >6 lbs), exposure to 
other children (presence of any older siblings or 
attendance at daycare with other children before 3 
months)  
Savilahti 
2005 40 
Multivariate stepwise logistic regression analysis by the forward selection method. 
Associations with symptoms of atopy and verified atopy were studied among the 
whole study group, those with long or short breast-feeding, and those with or without 
family history for atopy. 
GM (95% CI) 
OR (95%CI) 
 
* Logarithmically transformed 
NR 
Rigotti 
2006 38 
Independent samples t-test for normally distributed variables and the Mann–Whitney 
U-test for variables not normally distributed for the differences between two unpaired 
groups. 
Median (range) 
 
The two groups of mothers were comparable for aging, 
alimentary habits, and pregnancy course. 
NR 
Snijders 
2006 41 
ANOVA for comparisons of concentrations between groups. 
Logistic regression analysis for association between cytokines and infant’s atopic 
manifestations. 
Extreme values of concentrations of cytokines were not excluded as these did not 
influence the results. 
Mean (SD) 
OR (95%CI) 
Recruitment group (conventional vs. alternative) 
Time interval between birth and HM collection (days) 
Total storage time in freezer until analysis (days) 
Maternal characteristics: age, allergic history, season of 
breast milk collection, use of probiotics, infection (during 
week of HM collection) 
Offspring characteristics: number of older siblings 
Tomicic 
2010 21 
Mann-Whitney U test for unpaired analyses. 
Spearman’s rank-order correlation coefficient test for correlation analyses. 
The 2-test for categorical variables, and the Fisher’s exact test for when the expected 
frequency for any cell was 5. 
Median (range) 
rho 
 
NR 
Soto-
Ramirez 
2012 25 
Intra-class and Spearman correlation for associations of serum and whey immune 
markers. 
Log-linear regression for associations between immune markers and asthma-like 
symptoms at age 6 months and ever asthma-like symptoms in the first year of life 
(supplemental material). 
GEE was applied to predict repeated occurrence of asthma-like symptoms in infants 
at ages 6 and 12 months. In addition, models excluding infants who had both wheezy 
bronchitis and asthma-like symptoms were also ran. 
RR (95%CI) Maternal characteristics: race, age at pregnancy, smoking 
during pregnancy, household cigarette use at ages 6 and 
12 months, maternal history of asthma, eczema, rhinitis, 
consumption of antibiotics during pregnancy, vaginal 
infections/pelvic conditions during pregnancy 
Offspring characteristics: gender, any respiratory 
infections at ages 6 and 12 months, season of birth 
** FDR adjustment 
Joseph 
2014 34 
 
Chi-square tests for subgroup comparisons of participant characteristics for binary and 
categorical variables. Wilcoxon Rank Sum (WRS) test cytokine levels comparison. 
Student's t-tests for comparison of continuous variables. 
Logistic regression model for each atopic phenotype with the log-transformed TGFβ1 
values and the variable of interest (infant race/ethnicity or maternal atopy), along with 
the interaction term. 
GM (95% CI) 
OR (95%CI) 
* Logarithmically transformed 
Maternal characteristics: atopic status 
Offspring characteristics: race/ethnicity 
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Orivuori 
2014 37 
Linear regression for association between levels of HM TGF-β1 and exposures 
occurring up to month 2 of age. 
Uni-/multivariate smoothed plots based on generalized additive regression modelling 
for graphical display of significant associations of dose variables and health outcomes. 
 
GM (95% CI) 
Quintiles 
* Logarithmically transformed 
Centre as fixed effect, general farming variable (living 
on a farm vs. not), multiplicative interaction terms, 
breastfeeding duration as a confounder and as a 
multiplicative interaction term, TGF- β1 dose variable 
Jepsen 
2016 33 
Cox regression for the association between cytokine levels with age at onset of eczema 
and recurrent wheeze during the first 3 years of life. 
Principal component analysis (PCA) was used to decompose the complex data set into 
fewer dimensions, reflecting the immunological intermediator correlation structure, 
and to extract patterns that describe the predominant variations in HM immune 
mediator levels. 
To avoid the effect of reverse causality, a sensitivity analysis was performed excluding 
all children with eczema diagnosis before end of exclusive breastfeeding. 
HR (95% CI) * Logarithmically transformed 
Delivery mode 
Household income 
Maternal eczema history 
Filaggrin mutation 
Household dog at birth and exclusive breastfeeding 
length  
** FDR adjustment 
Soto-
Ramirez 
2016 24 
Ordinal logistic regression for the effect of probiotics. 
Wilcoxon matched-pairs signed-rank test for comparison of concentrations at 2 time 
points. 
Linear regression for effect of probiotic supplementation on TGF-β concentrations. 
Causal mediation analysis (paramed) for breast milk cytokines which were found to 
be altered by probiotic supplementation. 
GEE adjusting for within-participant effects using the regular maximum likelihood 
method for determination of the role of TGF-β in scratching at ages 6 and 12 months. 
Median (IQR) 
OR (95%CI) 
RR (95%CI) 
* Logarithmically transformed 
Maternal characteristics: race, age at pregnancy, marital 
status, smoking during pregnancy, household cigarette use 
at ages 6 and 12 months, maternal and paternal history of 
eczema, consumption of acetaminophen during 
pregnancy, and vaginal or urinary infections during 
pregnancy 
 Offspring characteristics: gender and season of birth  
** FDR adjustment 
Munblit 
2017 35 
Univariate analysis and correlation matrix, followed by multivariate analysis which 
included modelling, using least absolute shrinkage and selection operator (LASSO) 
and generalized linear model (GLM). 
Median (IQR) 
OR (95% CI) 
 
* Binary variable-transformed (detectable vs. 
undetectable) 
Levels of growth factors in colostrum and HM, 
detectability of cytokines in colostrum and HM, 
site of collection, colostrum collection time, 
maternal atopic status, delivery type, infant gender 
ANOVA, analysis of variance; CI, confidence interval; CMA, cow’s milk allergy; FDR, false discovery rate; GEE, generalized estimating equation; GLM, generalized linear model; GM, geometric mean; HM, 
human milk; HR, hazard ratio; IQR, inter-quartile range; LASSO, least absolute shrinkage and selection operator; NR, not reported; OR, odds ratio; PCA, principal component analysis; RR, relative risk; SD, 
standard deviation; SEM, standard error of the mean; TGF-β, transforming growth factor beta; WRS, Wilcoxon Rank Sum. 
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TABLE SIII. Associations between TGF-β in human milk and allergic outcomes in children 
Reference 
 
Age at 
outcome 
assessment 
TGF-β isoform and 
time 
of collection 
 Associations between human milk TGF-β and allergic outcomes  
Eczema (interventional studies) 
Rautava 2002 31 2 y.o TGF-β1,2 (MM) 3 mo NS (data not shown) 
Bottcher 2008 10 2 y.o TGF-β1,2 (C) 3d NS (data not shown) 
  TGF-β1,2 (MM) 1 mo NS (data not shown) 
Prescott 2008 30 2 y.o TGF-β1 (C) 3-7d NS (data not shown) 
  TGF-β1  (MM)  1 and 3 mo NS (data not shown) 
Kuitunen 2012 12 2 y.o  
Atopic E 2 y.o 
TGF-β2 (C) 0-3d 
 
NS: OR, 1.05; 95% CI ,0.61-1.79  
NS: OR, 1.16; 95% CI, 0.57-2.34 
 2 y.o TGF-β2 (MM) 3 mo ↑TGF-β2 (MM) - ↑higher risk of E by the age of 2 years (OR, 2.30; 95% CI, 1.34-3.94) 
 Atopic E 2 y.o  NS: OR, 1.51; 95% CI, 0.77-2.96 
Ismail 2013 11 1 y.o TGF-β1 (TM) 7 d No E (451.3 (330.4725.4)) vs. E (450.4 (357.2798.7)): NS, P = 0.7; aP = .9 
  TGF-β1 (MM) 28 d No E (284.9 (200433.6)) vs. E (269.3 (200366.0): NS, P = 0.7; aP = 0.6 
Simpson 2016 13 2 y.o TGF β1-3 (TM) 10 d NS (data not shown) 
  TGF β1-3 (MM) 3 mo NS (data not shown) 
   Eczema (observational studies) 
Kalliomaki 1999 6 1 y.o TGF-β1,2 (C) 0d 
 
 
↑TGF-β1 - ↑higher post-weaning onset of E compared with no onset (P = .0056) and pre-weaning onset (P = .0008); 
↑TGF-β2 - ↑higher post-weaning onset of E compared with pre-weaning onset (P = .015) and comparable to nonatopic 
control subjects. 
TGF-β1,2 (MM) 3 mo NS 
Savilahti 2005 40 4 y.o TGF-β1,2 (C) 1-4 d NS (data not shown) 
Snijders 2006 41 1 y.o  
TGF-β1 (MM) 1 mo NS: 
Low (2.0-166.9 pg/ml): aOR, 1.0; 95% CI, reference; n = 30 
Middle (166.9-248.4 pg/ml): aOR, 1.14; 95% CI, 0.59-2.10; n = 32 
High (248.5-1536.8): aOR, 1.00; 95% CI, 0.53-1.91; n = 28 
P-value for trend: aOR, 1.00; 95% CI, n = 299  
Rigotti 2006 38 6 mo TGF-β1 (C) 3d TGF-β1 (MM) 1 mo 
4/6 infants who developed E received milk with no TGF-β1 in both C and MM. No statistical analysis has been performed. 
Tomicic  2010 21 2 y.o TGF-β1,2 (C) 0-4 d 
TGF-β1,2 (MM) 1 mo 
NS (data not shown) 
Orivuori 2014 37 2 y.o 
 
TGF-β1 (MM) 2 mo NS: aOR, 0.86; 95% CI, 0.65-1.14. 
all NS (aOR, 95% CI): Q1, 1.00; Q2, 0.95, 0.48-1.90; Q3, 1.12, 0.58-2.16; Q4, 0.64, 0.30-1.34; Q5, 1.00, 0.50-1.98. 
4 y.o NS: aOR, 0.83; 95% CI, 0.63-1.08. 
all NS (aOR, 95% CI): Q1, 1.00; Q2, 0.77, 0.40-1.51; Q3, 1.13, 0.60-2.12; Q4, 0.87, 0.45-1.71; Q5, 1.10, 0.57-2.09. 
Jepsen 2016 33 3 y.o TGF-β1 (MM) 1 mo NS: HR 0.89; 95% CI, 0.72-1.10; P = 0.29; aHR 0.91; 95% CI, 0.74-1.12 
Soto-Ramirez 2016 24 Scratching 1 y.o TGF-β1 (MM) 21d NS: 
TGF-β1 level ≥774.63: RR, 0.71; 95 % CI, 0.48-1.05 
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Level 438.28–774.63: RR, 0.98; 95 % CI, 0.73-1.31 
Level <436.28 - reference. 
Munblit 2017 35 6 mo. TGF-β2 (C) 0-6 d NS: aP = 0.66 
TGF-β2 (MM) 1 mo ↑TGFβ2 (MM) - ↑higher risk of E (aOR, 1.04; 95% CI, 1.01–1.06) 
NS: aP = 0.087 
TGF-β3 (C) 0-6 d NS: aP = 0.17 
TGF-β3 (MM ) 1 mo NS: aP = 0.66 
Atopic sensitization ( interventional studies) 
Rautava 2002 31 2 y.o TGF-β1,2 (MM) 3 mo NS (data not shown) 
Bottcher 2008 10 2 y.o TGF-β1 (C) 3 d NS (data not shown) 
↓TGF-β2 (C) [<701**] ↓AS during first 2 years: OR, 0.3; 95% CI, 0.1-0.9 
TGF-β2 (C) [>1400] AS at 6 months: NS: aOR, 5.0; 95% CI, 0.9-27 
TGF-β1,2 (MM) 1 mo NS (data not shown) 
Huurre 2008 29 1 y.o TGF-β2 (C) 0 d NS (data not shown) 
Prescott 2008 30 2 y.o TGF-β1 (C) 3-7 d NS (data not shown) 
TGF-β1 ( MM) 1 and 3 mo NS (data not shown) 
Ismail 2013 11 1 y.o TGF-β1 (TM) 7 d NS (data not shown) 
TGF-β1 (MM) 28 d NS (data not shown) 
Simpson 2016 13 2 y.o TGF β1-3 (TM) 10 d NS (data not shown) 
TGF β1-3 (MM) 3 mo NS (data not shown) 
Atopic sensitization (observational studies) 
Saarinen 1999 39 
 
1 y.o TGF-β1 (C) 1-4 d ↑TGF-β1 (C) - ↓SPT to CM (r = -0.228, P = .02); ↓SI to α-casein (r = -0.282, P = .04) and ↓SI to β-lactoglobulin (r = -
0.347, P = .01); 
NS: sIgE  to CM (r = -0.138, P = .18); SI to β-casein (r = -0.241, P = .08). 
Bottcher 2003 32 2 y.o TGF-β1,2 (C) 0-4 d 
TGF-β1,2 (MM )1 mo 
NS (data not shown) 
NS (data not shown) 
Savilahti 2005 40 4 y.o TGF-β1,2 (C) 1-4 d NS (data not shown) 
Snijders 2006 41 2 y.o TGF-β1 (MM) 1 mo NS: Low (2.0-166.9 pg/ml): aOR, 1.0; 95% CI, reference; n = 17. 
Middle (166.9-248.4 pg/ml): aOR, 1.19; 95% CI, 0.52-2.74; n = 21. 
High (248.5-1536.8 pg/ml): aOR, 0.51; 95% CI, 0.21-1.24; n = 12. 
P-value for trend: aOR, 0.13; 95% CI, n = 200. 
Tomicic 2010 21 2 y.o TGF-β1,2 (C) 0-4 d NS: In Sweden (median, 486; range, 240-1400 pg/mL, in non-sensitized vs. median 586; range, 365-1156, in sensitized infants; 
P = .11). 
Joseph 2014 34 3 y.o TGF-β1 (MM) 1 mo ↓GM in non-atopic mothers of infants with elevated vs. not elevated sIgE (1347 vs. 1651 pg/ml respectively, P = .047) ↑GM in atopic mothers of infants classified as allergen-specific IgE (2161 vs. 1525 pg/ml respectively, P = .001). 
Orivuori 2014 37 4 y.o TGF-β1 (MM) 2 mo NS: aOR, 1.10; 95% CI, 0.85-1.42. 
Based on IgE cut-off 0.35Ku/l: 
All NS (aOR, 95% CI): Q1, 1.00; Q2, 1.10, 0.60-2.01; Q3, 1.03, 0.56-1.91; Q4, 1.46, 0.79-2.70; Q5, 1.76, 0.93-3.32. 
All other cut-offs/ages: NS, P > .05. 
6 y.o NS: aOR,1.05; 95%-CI, 0.82-1.36. 
Based on IgE cut-off 0.35Ku/l: 
All NS (aOR, 95% CI): Q1, 1.00; Q2, 0.75, 0.41-1.35; Q3, 1.04, 0.56-1.93; Q4, 0.84, 0.46-1.53; Q5, 1.02, 0.55-1.89. 
Based on IgE cut-off 3.5 kU/l (aOR, 95% CI): Q1, 0.40, 0.18-0.90; Q2, 0.26, 0.11-0.61. 
All other cut-offs/ages: NS, P > .05. 
Munblit 2017 35 6 mo TGF-β1-3 (C) 0-6 d 
TGF-β1-3 (MM) 1 mo 
NS (data not shown) 
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Asthma/wheezing (observational studies) 
Oddy 2003 36 Asthma-like 
symptoms 1 y.o 
TGF-β1 (TM) 14 d 
 
NS (P = .18). 
↑Dose of TGF-β1 (TM) - ↓lower risk of wheeze (%) (P = .017), relationship is linear (P = .006 trend χ2). 
↑ Dose of TGF-β1 (TM) - ↓lower risk of wheeze (OR, 0.22; 95% CI, 0.05-0.89). 
Savilahti 2005 40 A 4 y.o TGF-β1,2 (C) 1-4 d NS (data not shown) 
Snijders 2006 41 W 2 y.o TGF-β1 (MM) 1 mo NS: Low (2.0-166.9 pg/ml): aOR, 1.0; 95% CI, reference; n = 24. 
Middle (166.9-248.4 pg/ml): aOR, 1.21; 95% CI, 0.61-2.93; n = 28. 
High (248.5-1536.8 pg/ml): aOR, 1.13; 95% CI, 0.57-2.23; n = 28. 
P-value for trend: aOR, 0.73; 95% CI, n = 299. 
Soto-Ramirez 2012 25  Asthma-like 
symptoms 1 y.o 
TGF-β1 (MM) 21 d ↑TGF-β1 (MM, 4th and 3d quartile levels) - ↓lower risk of asthma-like symptoms (RR, 0.31; P = .01 and 0.26, P = .002 
respectively). 
Orivuori 2014 37 A 4 y.o TGF-β1 (MM) 2 mo NS: aOR, 0.77; 95% CI, 0.47-1.27. 
All NS (aOR, 95% CI): Q1, 1.00; Q2, 0.57, 0.18-1.84; Q3, 0.43, 0.12-1.50; Q4, 0.53, 0.15-1.87; Q5, 0.65, 0.21-2.02.  
A 6 y.o NS: aOR, 0.92; 95% CI, 0.62-1.38. 
All NS(aOR, 95% CI):Q1, 1.00; Q2, 0.90, 0.37-2.20; Q3, 0.43, 0.15-1.24; Q4, 0.83, 0.32-2.13; Q5, 0.70, 0.27-1.82. 
Jepsen 2016 33 W 3 y.o TGF-β1 (MM) 1 mo NS: HR, 0.91; 95% CI, 0.68-1.23; P = .54; aHR, 0.90; 95% CI, 0.66-1.22 
Munblit 2017 35 W 6 mo TGF-β2 (C) 0-6 d NS: aP = 0.283 
TGF-β2 (MM) 1 mo NS: aP = 0.090 
TGF-β3 (C) 0-6 d NS: aP = 0.193 
TGF-β3 (MM) 1 mo NS: aP = 0.283 
Food allergy (interventional studies) 
Rautava 2002 31 CMA 2 y.o TGF-β1,2 (MM) 3 mo NS (data not shown) 
Food allergy (observational studies) 
Saarinen 1999 39 
 
CMA 1 y.o TGF-β1 (C) 1-4 d ↓TGF-β1 (Cinfants with later development of IgE-mediated CMA) - ↑ non-IgE-mediated CMA (t = 2.57, P = .012). 
The level of control subjects did not differ from both groups. 
Savilahti 2005 40 CMA 4 y.o TGF-β1,2 ( C) 1-4 d NS (data not shown) 
Joseph 2014 34 3 y.o TGF-β1 (MM)1 mo TGF-β1 (MMAmong non-black infants) - FA vs. no FA: NS (P = .081); SPT+ food allergens vs. SPT-: NS (P = .064) 
Munblit 2017 35 6 mo. TGF-β2 (C) 0-6 d NS: aP = 0.91 
TGF-β2 (MM) 1 mo NS: aP = 0.98 
TGF-β3 (C) 0-6 d NS: aP = 0.49 
TGF-β3 (MM) 1 mo NS: aP = 0.91 
Allergic rhinitis/conjunctivitis (observational studies) 
Savilahti 2005 40 ARC 4 y.o TGF-β1,2 ( C) 1-4 d NS (data not shown) 
Studies with combined allergic outcomes (interventional studies) 
Kuitunen 2012 ***12 AlD 2 y.o  TGF-β2 (C) 0-3 d 
 
NS: OR, 1.05; 95% CI, 0.62-1.76 
AlD 5 y.o NS: OR, 1.08; 95% CI, 0.66-1.77 
AtD 2 y.o NS: OR, 1.31; 95% CI, 0.66-2.62 
AtD 5 y.o NS: OR, 1.06; 95% CI, 0.63-1.79 
AlD 2 y.o TGF-β2 (MM) 3 mo ↑TGF-β2 (MM) - ↑higher risk of allergic disease by the age of 2 years (OR, 2.23; 95% CI, 1.33-3.74) 
AtD 2 y.o NS :OR, 1.74; 95% CI, 0.90-3.37 
AlD 5 y.o NS: OR, 1.36; 95% CI ,0.84-2.21  
AtD 5 y.o NS: OR, 1.04; 95% CI, 0.62-1.73 
Studies with combined allergic outcomes (observational studies) 
Bottcher 2003 32 E 2 y.o TGF-β1,2 (C) 0-4 d 
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 A 2 y.o TGF-β1,2 (MM) 1 mo NS: the number of positive samples or the levels of the cytokines in C or MM and the development of either allergic symptom 
(P-values: .14 - .99). 
 
ARC 2 y.o 
A, asthma; AlD, allergic diseases; AtD, ‘atopic’ diseases; aHR, adjusted hazard ratio; aOR, adjusted odds ratio; aP, adjusted P-value; AR, allergic rhinitis; ARC, allergic rhinoconjunctivitis; AS, allergic sensitization; 
C, colostrum (0-4 days); CI, confidence interval; CM, cow’s milk; CMA, cow’s milk allergy; D, days; DNS, data not shown (not presented in the paper); E, eczema; FA, food allergy; FDR, false discovery rate 
(adjusted); GM, geometric mean; HR, hazard ratio; IQR, inter-quartile range; MA, multivariate analysis; MM, mature human milk (2 weeks and later); MO, months; NA, non-applicable; NR, not reported; NS, non-
significant; OR, odds ratio; Q, quintile; RR, relative risk; SD, standard deviation; SI, stimulation index – expression of proliferation (median counts per minute incorporated in the presence of the antigen divided by 
median counts per minute incorporated in the absence of the antigen); SPT, skin prick test; sIgE, specific IgE levels; TGF-β, transforming growth factor beta; TM, transitional milk (5-14 days); W, wheezing. 
“↑” – stands for increased and “↓” – stands for decreased levels or reduced risk of TGF-β or disease/parameter; * Age, up to which outcomes were assessed; ** All concentrations are pg/ml; *** This study analyzed 
eczema separately and also combined allergic diseases for the analysis (eczema, food allergy, allergic rhinitis and asthma) and atopic (IgE-associated) allergic diseases. 
